Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks el jefe! Looking forward to it...
Do you believe anyone posts anything positive for any other reason than personal interest? ;)
I just bought in a couple of days ago, lots of excitement going on here... I have read everything I can find and agree it should head to pennies easily...can you elaborate on how we could be valued at .20 (would be more than happy to see it at .20)
Do you believe you have anything to do with the share price getting to .02??? to getting anywhere???
Very happy my .042 purchase order didn't go through last week
The share price does me no good here
You're kidding right?
Aug 25, 2010
"Regarding any reverse split, no such proposal has yet been discussed.
This was written nearly 6 months ago...they very well might not have discussed a RS up until that point...Nothing says they haven't talked about it from Aug 25 till today!
"unless you're trying to buy cheaper shares"
HAHA I do NOT want any more shares of this garbage
IMO
Watson does not give a dogcrap about the bag holders that financed his failed company
Certainly IMO, I have no idea what the company is going to do...Just joking around with Deano...
You'll have to break into your piggy bank for coffee money after they RS.
My position exactly dahbmw...Silence is my most unliked attribute of a company.
Good to know, thanks penney
so do you think we will keep our grdo shares or is it possible for a new csi ticker
:) haha I knew it was going to go up today, do I decided to stick around to see what happens.
Credo-TM, a private entity, was created by a group of professors and doctors from one of Russia's oldest and largest human physiological health laboratory. The company is based in the Techno Park area of Kazan City in the Russian Federation. Over the past several years Credo-TM has developed, with the help of government grants, a solid distribution network of advanced and modern medical products in countries such as Russia, Belarus, Ukraine and Kazakhstan. Close to 1200 medical centers and hospitals are using the services of Credo-TM today. The Company's initial effort was the distribution of diagnostic tests for diabetes, pregnancy as well as tuberculosis (early stage). Over the past 3 years, more than 300 employees have joined Credo-TM.
Phone: +7 (843) 272-89-24 - Business Hours: 9-17 (Local Time)
Credo-TM, a private entity, was created by a group of professors and doctors from one of Russia's oldest and largest human physiological health laboratory. The company is based in the Techno Park area of Kazan City in the Russian Federation. Over the past several years Credo-TM has developed, with the help of government grants, a solid distribution network of advanced and modern medical products in countries such as Russia, Belarus, Ukraine and Kazakhstan. Close to 1200 medical centers and hospitals are using the services of Credo-TM today. The Company's initial effort was the distribution of diagnostic tests for diabetes, pregnancy as well as tuberculosis (early stage). Over the past 3 years, more than 300 employees have joined Credo-TM.
Phone: +7 (843) 272-89-24 - Business Hours: 9-17 (Local Time)
JAN. 18, 2011...NEURO-BIOTECH CORP. ANNOUNCES THE SIGNING OF ITS FIRST EXCLUSIVE LICENSE AGREEMENT WITH CREDO-TM CORP. FOR DISTRIBUTION OF ITS PRODUCTS IN THE RUSSIAN FEDERATION
BASEL, Switzerland, jan. 18, 2011, Neuro-Biotech Corp. (OTCQB: MRES) announces that it has concluded a Business Development Agreement with Credo-TM, a Russian company.
The Agreement provides for an exclusive right to distribute all Neuro-Biotech proprietary blood analysis kits and NeuroCeuticalsâ„¢ in territories such as Russia, Belarus, Ukraine and Kazakhstan. Furthermore this agreement binds Credo-TM to a minimum yearly order of 500,000 test units for a term of 10 years. Both parties have agreed on an initial price of $55.00 USD per unit for its initial launch. The pricing for subsequent years may be subject to change.
PROJECTED MARKET PENETRATION AND REVENUE
In United States alone, the health care sector includes more than 780,000 hospitals (Ref: First Research), clinics, doctor offices, emergency care units, nursing homes and social services providers. That figure includes 3059 Mental Health care institutions with 77 million people living in them. It would take 5,145 doctors? to meet their needs. Those 77 million people will need at least 1 test to evaluate their level, reducing by the fact the number of practitioners. (Ref: Kaiser State Health Facts, Office of Shortage Designation, Bureau of Health Professions, Health Resources and Services Administration (HRSA), data as of 9/30/08)
Now let say that the 780,000 health care centers order just one test per day each, it is relatively easy to make a simple calculation when the average selling price per test is around $50. Those figures are valid for the United States and only for the first test and we have 12 licenses!
The SymPath® has already been tested on several thousand people in the world with an accuracy of 98.8%.
For more information, do not hesitate to contact us by writing to info@neuro-agora.com and your request will be transferred to the appropriate persons and we will get back to you as soon as possible.
As long as it isn't the storm that sinks our ship, I'm happy
Fundamentals!
SymPathâ„¢the first diagnostic test of stress-related diseases.
Stress is a significant worldwide concern. It is now more easy to assess the overall economic impact of stress, non only in healthcare costs but also in lost productivity within the workplace (Worldwide Health Organisation, 2000; International Labor Office of Geneve, 2000). A study done by Ernst & Young (1997) has estimated that 30-50% of visits to general practitioners' offices are for stress-related disorders. Neuro-Biotech Corporation as a results of years of study, has developed diagnotic tools involving the Hypothalamo-Hypophyso-Pituitary-Adreno-Sympathetic (HPAS) axis, to detect at an early stage the ability of an individual to cope with internal and external stress factors. So, SymPathâ„¢, will play an important role in the prevention, early diagnosis, monitoring and therapeutic follow-up for health disorders related to stress and socio-professional related-diseases.
SymPathâ„¢, is the first clinically proven diagnostic kit that provides clinical measurement of stress through specific bio-indicator released within the blood. SymPathâ„¢ can assess the Sympathetic Nervous System (SNS) impact on physical health, providing an early detector for stress-related diseases such as Essential Hypertension, Anxiety, Chronic Fatigue Syndrom, Depression, Panic Syndrom, Hypoglycemia, Fibromyalgia etc., and so, being used for an early diagnotic program.
SymPathâ„¢ benefits :
* Non-invasive test
* 98% reliability
* Quantitative results
* No hospitalization
* No more therapeutic trials and errors
* Therapeutic follow-up
* No substance medical interference
US PATENT http://neuro-biotechcorp.com/applications/neuro-biotechcorp.com/groupware/files/personal/1/neuro-biotech_sympath_patent%281%29.pdf
Neuro Bio Test 1:
SymPathâ„¢, is the first clinically proven diagnostic kit that provides clinical measurement of stress through specific bio-indicator released within the blood
SymPath™, new diagnostic test in vitro allowing, from a blood sample, to evaluate quantitatively the dopamine-ß-hydroxylase activity, noradrenaline synthesizing enzyme related to the function of the Sympathetic Nervoux Symtem (SNS).
SymPathâ„¢ allows to distinguish depressive states from anxious disorders.
SymPathâ„¢ a blood test to prescribe in all health check-ups.
SymPathâ„¢ a reliable clinical index expected by all medical communities.
New diagnostic test in vitro allowing, from a blood sample, to evaluate quantitatively the dopamine-ß-hydroxylase (DBH) activity, noradrenaline synthesizing enzyme related to the function of the Sympathetic Nervoux Symtem (SNS).
Working together for mankind well-being
Neuro-Biotech Corp. - Mission
To promote the mental health, the life quality and well-being of people around the world.
To maintain recognized worldwide status as a leader in development and commercialization of innovative healthcare products for the diagnosis, monitoring and treatment of clinical neuroscience-related diseases.
To provide employees with a working environment that favours personal and professional growth.
To ensure that corporate partners, investors and shareholders enjoy a superior return on investment.
Neuro-Biotech Corp. - Ethics
Respect of the GLPs norms for all products, blood sampling centres and associated laboratories.
Training for all employees about the methods related to the procedures' standardization.
Respect of the GMPs norms for suppliers and manufacturing procedures.
Approval of all products for all market penetrations.
Huge Contract Worth 275 Million
Tuesday 18, January 2011
NEURO-BIOTECH CORP. ANNOUNCES THE SIGNING OF ITS FIRST EXCLUSIVE LICENSE AGREEMENT WITH CREDO-TM CORP. FOR DISTRIBUTION OF ITS PRODUCTS IN THE RUSSIAN FEDERATION
BASEL, Switzerland, jan. 18, 2011, Neuro-Biotech Corp. (OTCQB: MRES) announces that it has concluded a Business Development Agreement with Credo-TM, a Russian company.
The Agreement provides for an exclusive right to distribute all Neuro-Biotech proprietary blood analysis kits and NeuroCeuticalsâ„¢ in territories such as Russia, Belarus, Ukraine and Kazakhstan. Furthermore this agreement binds Credo-TM to a minimum yearly order of 500,000 test units for a term of 10 years. Both parties have agreed on an initial price of $55.00 USD per unit for its initial launch. The pricing for subsequent years may be subject to change.
NEURO-BIOTECH CORP. ANNOUNCES, HAVING NOW REACHED DEBT FREE STATUS, AND CURRENTLY PLANNING ITS DISTRIBUTION PROGRAM FOR 2011
BASEL, Switzerland, le 14 déc. - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) announced today having now reached debt free status, and currently planning its distribution program for 2011.
After 2 years of hard work and administrative organisation to finance and bring to market the distribution of its products, Neuro-Biotech Corp. is proud to inform its shareholders that it has repaid all debts to third parties totalling the sum of one million, one hundred, twenty five thousand and nine hundred thirteen dollars ($ 1,125,913).
SymPath has been the subject of more than 5,000 clinical tests
NEURO-BIOTECH CORP. RELEASES A LIST OF ANSWERS REGARDING NUMEROUS ENQUIRIES
BASEL, SWITZERLAND, Nov. 22 - Neuro-Biotech Corp. (OTCQB: MRES) publishes answers to the most frequently asked questions.
The topic commonly asked about is in regards to Company's statements that no further R&D needs to be carried out on the 16 products that have been licensed. This technical platform was bought from a university following 20 years of research for the sum of $3 million. A total of $5 million was spent by the end of 2000 and subsequently, in the last 10 years research and development has yielded 16 products that are ready for production.
Neuro-Biotech's first blood test, SymPath has been the subject of more than 5,000 clinical tests
Huge Contract Worth 275 Million
Tuesday 18, January 2011
NEURO-BIOTECH CORP. ANNOUNCES THE SIGNING OF ITS FIRST EXCLUSIVE LICENSE AGREEMENT WITH CREDO-TM CORP. FOR DISTRIBUTION OF ITS PRODUCTS IN THE RUSSIAN FEDERATION
BASEL, Switzerland, jan. 18, 2011, Neuro-Biotech Corp. (OTCQB: MRES) announces that it has concluded a Business Development Agreement with Credo-TM, a Russian company.
The Agreement provides for an exclusive right to distribute all Neuro-Biotech proprietary blood analysis kits and NeuroCeuticalsâ„¢ in territories such as Russia, Belarus, Ukraine and Kazakhstan. Furthermore this agreement binds Credo-TM to a minimum yearly order of 500,000 test units for a term of 10 years. Both parties have agreed on an initial price of $55.00 USD per unit for its initial launch. The pricing for subsequent years may be subject to change.
TOU States you are not allowed to comment on other groups of posters...You may very well get banned for such nonsense.
Ha Ha! Ok you can have them Deano... Honestly, I do hope this turns out to be a great company...I was just expecting a different result from the grand opening and FDA approval news.
They are selling meds themselves...they have their own line
The OS won't change until the AS is increased imo
What are the revenues???? does anyone have any clue...no imo
I'm not selling to you Deano.
What is so awesome about the fundamentals??? The billion outstanding shares?
That's very sad if this is the best penny you have found...keep your chin up, you'll find a good one some day
Mine are going up next week...too many out there with much better SS and investor relations...Best of luck with your investments BLUE
This stock PRICE is on drugs(imo)...BOOO MXLO
CR&P Holdings is far from CRAP!!!lol Might be the longest weekend ever. Congratulations EVERYONE... It is straight up hill from here!!!
HIGH 5 RED